HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB)
← catalyst calendarSponsored by Altimmune, Inc. (industry) · ALT — their whole pipeline →.
Phase
Phase 2
Status
Terminated
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
87actual
Sites
21
Countries
Canada, Germany, Spain +2
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-31
Why the sponsor stopped it
Did not meet endpoints
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-12-26 | actual | When the study began enrolling |
| Primary completion | 2024-03-27 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2024-04-17 | actual | The whole study's end, after follow-up |
| First posted | 2020-12-28 | actual | When this record first appeared on the registry |
| Results posted | 2025-12-08 | actual | When the sponsor posted results to the registry |
| Record updated | 2025-12-08 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Hepatitis B, Chronic
Interventions
- Biological: HepTcell
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFThe Proportion of Patients Achieving Virologic Responses
measured Baseline to Day 169
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2022-07-24 · 1.1 MB · Prot_000.pdf
Statistical Analysis Planposted 2024-04-22 · 931 KB · SAP_001.pdf
Related
ALT's other studiesmost recently updated first
- Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH Phase 3 · Recruiting
- RESTORE TRIAL: Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD) Phase 2 · Active, not recruiting
- RECLAIM STUDY: Phase 2 Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight Phase 2 · Completed
- IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH) Phase 2 · Completed
- NasoShield Study of Safety and Immunogenicity Phase 1 · Completed
Permalink · ALT's whole pipeline · Catalyst calendar · Every registered study · What changed